Psoriasis drug gets new warning
From Times Wire Services
The Food and Drug Administration said it would update the labeling of Genentech Inc.’s psoriasis drug Raptiva to highlight the risk of several bacterial and viral conditions.
The added warnings follow Genentech’s announcement this month that Raptiva might have contributed to a patient getting progressive multifocal leukoencephalopathy, or PML, which causes swelling of the brain and is usually fatal.
